Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
LONDON - Morgan Stanley & Co. International plc issued a corrective notice Thursday regarding Verisure plc’s initial public offering, clarifying that no exercise of the overallotment option has occurred, contrary to an earlier statement made the same day.
The investment bank had erroneously announced that it had exercised in full the overallotment option to acquire up to 33,042,453 ordinary shares of Verisure at the offer price of €13.25 per share.
According to the correction, the stabilization period for Verisure’s IPO remains active and is expected to continue until November 7, 2025. Morgan Stanley, acting as the stabilization manager, confirmed that no stabilization activities have been undertaken so far in relation to the offering.
Verisure’s initial public offering consisted of 220,283,021 ordinary shares, excluding the overallotment option and subscriptions. The shares are trading under the ISIN code GB00BVMN1558.
The corrective notice follows a pre-stabilization announcement that was made on October 8, 2025.
The securities have not been registered under the United States Securities Act of 1933 and are not being offered in the United States, according to the press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.